BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32356386)

  • 21. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer.
    Umar SM; Kashyap A; Kahol S; Mathur SR; Gogia A; Deo SVS; Prasad CP
    Exp Cell Res; 2020 Nov; 396(1):112282. PubMed ID: 32919954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Myc-driven glycolysis via TXNIP suppression is dependent on glutaminase-MondoA axis in prostate cancer.
    Qu X; Sun J; Zhang Y; Li J; Hu J; Li K; Gao L; Shen L
    Biochem Biophys Res Commun; 2018 Oct; 504(2):415-421. PubMed ID: 30103944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer.
    Yuan XN; Shao YC; Guan XQ; Liu Q; Chu MF; Yang ZL; Li H; Zhao S; Tian YH; Zhang JW; Wei L
    Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119716. PubMed ID: 38547933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
    Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
    Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 31. Interactions between Myc and MondoA transcription factors in metabolism and tumourigenesis.
    Wilde BR; Ayer DE
    Br J Cancer; 2015 Dec; 113(11):1529-33. PubMed ID: 26469830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
    Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
    Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
    Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A; Pop LA; Zanoaga O; Ciocan-Cârtiţă CA; Cojocneanu R; Moldovan C; Raduly L; Pop-Bica C; Trif M; Irimie A; Berindan-Neagoe I; Braicu C
    Cell Physiol Biochem; 2020 Jul; 54(4):648-664. PubMed ID: 32619350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 37. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer.
    Apaya MK; Shiau JY; Liao GS; Liang YJ; Chen CW; Yang HC; Chu CH; Yu JC; Shyur LF
    J Exp Clin Cancer Res; 2019 May; 38(1):187. PubMed ID: 31072371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
    Hu MH; Wu TY; Huang Q; Jin G
    Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.